Traws Pharma, Inc. Announces Financing up to 72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval
| TRAW Stock | 8.67 0.21 2.36% |
Slightly above 62% of Traws Pharma's investor base is looking to short. The analysis of overall sentiment of trading Traws Pharma stock suggests that many investors are alarmed at this time. Traws Pharma's investing sentiment can be driven by a variety of factors including economic data, Traws Pharma's earnings reports, geopolitical events, and overall market trends.
Traws |
Traws Pharma, Inc. , a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases including bird flu, today announced that it has entered into definitive agreements to raise up to 72.6 million before deduction of placement agents fees and other estimated offering expenses. The initial tranche of 20 million gross proceeds will come in at closing for the issuance and s
Read at finance.yahoo.com
 |
Traws Pharma Fundamental Analysis
We analyze Traws Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Traws Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Traws Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Traws Pharma is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Traws Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Traws Pharma stock to make a market-neutral strategy. Peer analysis of Traws Pharma could also be used in its relative valuation, which is a method of valuing Traws Pharma by comparing valuation metrics with similar companies.
Peers
Traws Pharma Related Equities
| ORGN | Origin Materials | 11.30 | ||||
| HDSN | Hudson Technologies | 1.97 | ||||
| SLOFF | Solstad Offshore | 0.00 | ||||
| ALB-PA | Albemarle | 0.02 | ||||
| EA | Electronic Arts | 0.27 | ||||
| NTES | NetEase | 1.63 | ||||
| AINSF | Ainsworth Game | 5.66 |
Additional Tools for Traws Stock Analysis
When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.